SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Success against TB - but resistance still a concern
Mon March 25th - The number of new TB diagnoses in England has nearly halved this decade – but scientists have warned of the continuing threat from antibiotic resistance. More
Drug that could tackle bowel cancer drug-resistance
Mon March 25th - British scientists have identified a third drug that could help tackle resistance to treatment when bowel cancer is treated with the latest therapies, it was announced today. More
RECENT COMMENTS
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...
BOOKS ON WOMEN'S HEALTH
guide to breast disorders guide to womb disorders guide to menopause Complete Women's Health: from The Royal College of Obstetricians and Gynaecologists For books and family gift ideas click here
OTHER NEWS OF INTEREST
WOMEN'S HEALTH NEWS FEED
RSS graphic XML Graphic
ENGLEMED HEALTH NEWS

PARP inhibitors could boost immunotherapy

Monday March 11th, 2019

PARP inhibitors could be combined effectively with immunotherapies to destroy tumours in several kinds of cancer, according to a joint Anglo-French project.

The inhibitors were developed to work by damaging the DNA in tumours – but the latest studies show they also stimulate the immune system to attack tumours.

This is because they "unmask" the cancers by triggering the release of a range of molecules that alert the immune system to disease, according to the new findings.

The findings have been published in the Journal of Clinical Investigation and result from joint work between The Institute of Cancer Research, London, and the Institut Gustave Roussy, France.

Researchers studied lung tumours and cells from triple-negative breast cancers.

Clinical trials are now planned in patients with lung, breast, prostate and bladder cancer.

Researcher Professor Chris Lord said: “The findings of this study substantially change our understanding of how PARP inhibitors work. We now know that they not only kill tumours by damaging their DNA, but also by attracting immune cells to attack them – acting as a sort of double-pronged attack.

“Immunotherapy is a genuinely brilliant cancer treatment but generally only for the 10 to 20% of people who respond to it. Finding the tumour is half of the battle in immunotherapy so by attracting the immune cells to the tumour, PARP inhibitors could enable the immunotherapy drug to target their attack.”

Dr Kotryna Temcinaite, Research Communications Manager at Breast Cancer Now, said: “These are really promising findings that show once more just how important PARP inhibitors could be in treating a number of cancers. Not only do these drugs interfere with tumour cells’ ability to repair DNA but this study suggests they may have additional effects in initiating an immune response, which could then be exploited using other treatments.

“Activating the immune system to attack tumours is an exciting approach that is beginning to show promise in breast cancer. We now look forward to seeing how the combination of PARP inhibitors and checkpoint inhibitors may work in clinical trials for breast cancer patients.”

Journal of Clinical Investigation 9 March 2019

Tags: Cancer | Europe | Men's Health | Pharmaceuticals | UK News | Women's Health & Gynaecology

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES